SerOptix Technology Platform: Spectra-Molecular Informatics (SMI)


In blood and other physiological fluids, spectral signals of thousands of natural molecules combine to present a complex but unique signature. When disease strikes, this molecular signature is altered. When this alteration includes fluorescent molecules, then the molecular signature based on intrinsic fluorescence distinguishes normal from disease samples.

SerOptix' technology detects the natural differences between normal and diseased samples, and thereby provides pivotal new information for the development of novel therapeutic and diagnostic products. Our current technology probes the relatively untapped domain of native or intrinsic fluorescence of biological fluids and tissues. This technology uses the combined power of selective sample extraction, mathematical algorithms and state of the art laser-based optical systems to amplify the divergence between healthy and disease-derived samples. Powerful computational methods adapted at SerOptix permit us to see beyond the normal variations and identify previously unrecognized molecular changes arising from, and causing disease. Our approach preferentially surveys the many classes of small molecules that are recognized to be major constituents of the molecular signature of both physiological and patho-physiological states and that are not the targets of genomic and proteomic approaches.

The SerOptix technology offers a unique strategy for the rapid elucidation of changes in molecular physiology for diseases where critical information concerning the biological effects of a disease would be valuable for the development of new diagnostic and therapeutic agents. The value of the SerOptix technology can be realized at several level of the discovery process and the company determines the appropriate stages to out-license new intellectual property based on the combined review of both scientific and business parameters.

The coupling of multiple analytical tools permits us to establish the specific molecular determinants producing the spectral changes and, of equal importance, provides the essential elements of a comprehensive information-base that may hold great value for the rapid correlation of spectral patterns and physiological changes associated with the specific disease target.

The central strategy for the acquisition, analysis and exploitation of the native spectral information described above has been called: Spectra-Molecular Informatics, or SMI, (described below in detail) and represents the underlying engine for the generation of new intellectual property on which SerOptix bases its business strategy. The parallel creation of proprietary normal and disease databases is expected to provide a sustainable portfolio of spectral leads and molecular profiles to support a series of disease-specific corporate relationships.

The company has applied the SMI technology to the evaluation of samples-derived from patients infected with Hepatitis C virus (HCV) as a Proof of Performance of this technology platform. Sufficient spectral data has been collected that demonstrates molecular differences between normal and disease that we intend to develop further through corporate partners into novel diagnostic or therapeutic products. The company is evaluating the opportunity to isolate and identify HCV-specific molecular markers as a further validation of the SMI approach and to secure an intellectual property position around these molecules for licensing and partner-based product development. To support these efforts, further instrument development will focus on the optimization and application of Intrinsic Fluorescence Information Technology (INFLIT) systems for rapid acquisition of spectral data of chromatographic peaks during elution as a source of high value spectral data to complement the Spectral Profiling steps of SMI.

Through these efforts SerOptix intends to produce a panel of proprietary disease-specific spectral and molecular leads, a comprehensive database including normal and disease SMI data, and a powerful discovery system, each offering significant utility and value for the pharmaceutical and diagnostic development process.

Spectra-Molecular Informatics (SMI) Application

Spectra-Molecular Informatics provides a powerful platform for the identification of disease-specific Molecular Targets from combined spectral, chromatographic, and structural data. For any selected disease program, the SMI approach sequentially engages specific elements of our core technology, yielding several internal milestones and a program portfolio of enhanced value for partnership and product development.

The application of SMI is implemented through a series of steps providing increasingly specific spectral information and understanding of molecular differences associated with a target disease. These steps, described in greater detail through the links below, provide the core data of the SMI database that will increase progressively in complexity, information content, and value with the continued expansion of our R&D programs and business strategies.

  • Spectra-Molecular Informatics Process

    1. Spectral Data Acquisition & Processing
    2. Identification of Disease-Specific Spectral Signals
    3. Molecules Carrying Disease-Specific Spectral Properties
    4. Assays for Drug Discovery, Therapeutic Product Development and Diagnostic Applications
  • Spectra-Molecular Informatics Database

    [ About SerOptix ] [ The SerOptix Process ]
    [ Investment News ] [ Industry News ] [ Media ]
    [ Career Opportunities ] [ Contact Us ][ Home ]

    Copyright© 2000 SerOptix,Inc
    All Rights Reserved